Vinconate is an indolonaphthyridine derivative and can stimulate the muscariic acetylcholine receptor.
Treatment with Vinconate (50 to 200 mg/kg p.o.) significantly increases dopamine concentrations in dialysate. Daily treatment with Vinconate (25 mg/kg) for 7 days also significantly increases dopamine and serotonin concentrations in dialysate[1]. Chronic treatment with Vinconate at a 10 mg/kg significantly ameliorats the reduction in [3H]QNB binding in the nucleus accumbens and cerebellum. Furthermore, this Vinconate treatment significantly enhances [3H]QNB binding in the frontal cortex and hippocampus compare with the vehicle-treated aged animals. Also, chronic treatment with Vinconate at the higher dose significantly elevates [3H]QNB binding in the hippocampal CA3 sector and dentate gyrus compare with the vehicle-treated aged animals. Chronic treatment with Vinconate at a dose of 10 mg/kg shows a significant reduction in [3H]HC binding only in the hippocampal CA1 sector compare with the vehicle-treated aged rats[2].
[1]. Iino T, et al. Effect of vinconate, an indolonaphthyridine derivative, on dopamine and serotonin concentrations in dialysate from the striatum of freely moving rats: brain microdialysis studies. J Pharmacol Exp Ther. 1996 Aug;278(2):614-9. [2]. Araki T, et al. Effects of vinconate on neurotransmitter receptor systems in aged rat brain. Environ Toxicol Pharmacol. 1996 Dec 20;2(4):343-9.